Key Investor Signals
Patent-protected cystic fibrosis program
VG2D Pharma holds rights to a / University of Reims-originated molecule and is linked to patent protection around pyridazinone compounds for cystic fibrosis treatment.
Public funding and deeptech validation
VG2D Pharma is backed by strong French public innovation signals, including 2024, BFTE support, and €445,000 of SATT Nord maturation funding for the underlying MucoPyf project.
Preclinical proof-of-concept work
VG2D Pharma has completed early in vitro and in vivo proof-of-concept work on its molecules before .
Other Positive Signals
- Selected by Challenges in its “100 Startups to Invest in 2026” ranking.
- Building a pipeline with several leads, including two cystic fibrosis programs and one confidential indication.
- Founding team combines pharma leadership, , and cystic fibrosis research expertise.
Team
Dr. Imane Wild
Co-founder & CEO
- Senior pharmaceutical executive with experience across R&D, , , market access, strategy, and global operations.
- Former Head of EUCAN at and former Global at .
- Former senior medical affairs leader at , with international experience across North America, APAC, LATAM, Russia, Turkey, and the Middle East.
- Brings the pharmaceutical development, patient access, and launch experience needed to turn academic science into a biotech company.
Dr. Frédéric Velard
Co-founder & CSO Biologics
- PhD and HDR in biology, with long-standing research experience at Université de Reims Champagne-Ardenne.
- Deep expertise in rare diseases, cystic-fibrosis-related bone disease, inflammation, and bone tissue bioengineering.
- Co-originator of the academic research behind MucoPyf, alongside Prof. Stéphane Gérard.
- Brings the disease biology and expertise behind VG2D Pharma’s cystic fibrosis program.
Prof. Stéphane Gérard
Co-founder & CSO Chemistry
- Professor of medicinal chemistry at Université de Reims Champagne-Ardenne.
- Brings medicinal chemistry and molecule-design expertise to VG2D Pharma’s therapeutic approach.
- Co-originator of the academic research that led to the MucoPyf program.
- Drives the chemistry side of the company: moving molecules from academic discovery toward optimized drug candidates.
Product
VG2D Pharma is developing patented small-molecule therapies for cystic fibrosis. Its lead program is an oral treatment designed to modulate CFTR while also addressing inflammation and other disease complications.
Broader mutation coverage
VG2D Pharma's molecule family is engineered to address class II to VI CFTR mutations. The aim is to reach patients whose genetic profiles are poorly covered by existing modulators.
CFTR modulation and inflammation
The molecules are designed to improve CFTR function while adding an anti-inflammatory effect. This approach could address the underlying protein defect and inflammatory burden through the same treatment.
Simplified oral dosing
The treatment is being developed as one oral tablet that can be taken at any time of day. This dosing format is intended to reduce pill burden and support long-term adherence.
Market Overview
Cystic fibrosis is a rare but commercially established therapeutic category. Approximately 105,000 people have been diagnosed across 94 countries, including close to 40,000 in the United States. Its lifelong nature creates sustained demand for treatments that modify the underlying disease.
have validated the biology and commercial potential of oral cystic fibrosis therapies. The global therapeutics market was valued at $12.05 billion in 2025 and is projected to reach $23.31 billion by 2031. Important gaps remain for patients with uncovered mutations, limited treatment response or access constraints.
People diagnosed with cystic fibrosis across 94 countries.
Children and adults living with cystic fibrosis in the United States.
Projected global market growth from 2025 to 2031.
Combined 2025 revenue from TRIKAFTA/KAFTRIO and ALYFTREK.
Comparable Outcomes
Vertex Pharmaceuticals
is the clearest success case in cystic fibrosis. The company built the dominant CFTR modulator franchise and turned cystic fibrosis into a multi-billion-dollar therapeutic category. Vertex reported $12.0 billion in total revenue in 2025, driven primarily by the continued performance of its cystic fibrosis therapies.
Concert Pharmaceuticals / CTP-656
developed CTP-656, a cystic fibrosis . Vertex acquired worldwide development and commercialization rights to the asset for $160 million upfront, with up to $90 million in additional milestones.
Enterprise Therapeutics / Roche
Enterprise Therapeutics developed a cystic fibrosis program based on , a small-molecule approach targeting an alternative chloride channel to CFTR. acquired the program for approximately £75 million upfront, giving Roche a Phase 1 pan-genotype cystic fibrosis program designed to potentially benefit a broader group of CF patients.
Have a question about VG2D Pharma?
Ask DealBio. We may research the answer or share selected questions with the company.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.